文献速递肾移植

高危肾移植受者迟发性巨细胞病毒病筛查的Markov分析

A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients.
PubMed 文献 · Clin J Am Soc Nephrol · 2017-10-12

该研究采用Markov决策分析模型,评估CMV高危(IgG阳性供者至IgG阴性受者)肾移植受者在抗病毒预防6个月后筛查迟发性CMV感染的成本效果。比较不筛查与每1、2、3、4周筛查五种策略,结果显示筛查频率增加可提升质量调整生命年,每2周筛查在广泛支付意愿阈值下最具成本效果。

要点

  • CMV高危肾移植受者预防后筛查可增加QALY并具成本效果
  • 每2周筛查在支付意愿14000-185000美元/QALY区间内占优
  • 筛查成本、住院费用、CMV发生率和移植物丢失影响结果稳健性

核心结论

  • 在CMV高危肾移植受者中,与不筛查相比,预防后筛查CMV病毒血症与QALY增益相关且似乎具成本效果。
  • 每2周筛查在广泛支付意愿阈值范围内是最具成本效果的策略。

研究设计与样本

  • 研究采用Markov决策分析模型,纳入无症状CMV、轻度CMV感染和需住院的CMV感染等临床状态的成本与效用。
  • 比较五种策略:不筛查及每1、2、3、4周筛查,重症CMV进展基于CMV复制动力学建模。
  • 计算增量成本效果比(ICER),并进行单因素和概率敏感性分析检验模型稳健性。

主要发现

  • 随着筛查频率增加,QALY呈增量增益。
  • 每4周筛查相比不筛查的ICER为783美元/QALY。
  • 每3周相比每4周筛查的ICER为1861美元/QALY。
  • 每2周相比每3周筛查的ICER为10947美元/QALY。
  • 每周相比每2周筛查的ICER为197086美元/QALY。

关键数值与推荐

  • 当支付意愿阈值低于14000美元/QALY时,不筛查更受偏好。
  • 当支付意愿阈值高于185000美元/QALY时,每周筛查更受偏好。
  • 在支付意愿14000-185000美元/QALY区间内,每2周筛查为占优策略。
  • 结果对筛查成本、住院费用、预防后CMV发生率和CMV感染后移植物丢失敏感。

临床怎么用

  • 对于CMV高危肾移植受者,抗病毒预防结束后可考虑每2周筛查CMV病毒血症以平衡成本与效果。
  • 决策需结合当地筛查成本、住院费用及CMV发生率等参数综合判断。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: Management strategies are unclear for late-onset cytomegalovirus infection occurring beyond 6 months of antiviral prophylaxis in cytomegalovirus high-risk (cytomegalovirus IgG positive to cytomegalovirus IgG negative) kidney transplant recipients. Hybrid strategies (prophylaxis followed by screening) have been investigated but with inconclusive results. There are clinical and potential cost benefits of preventing cytomegalovirus-related hospitalizations and associated increased risks of patient and graft failure. We used decision analysis to evaluate the utility of postprophylaxis screening for late-onset cytomegalovirus infection. DESIGN, SETTING, PARTICIPANTS, & MEASUREMENTS: We used the Markov decision analysis model incorporating costs and utilities for various cytomegalovirus clinical states (asymptomatic cytomegalovirus, mild cytomegalovirus infection, and cytomegalovirus infection necessitating hospitalization) to estimate cost-effectiveness of postprophylaxis cytomegalovirus screening strategies. Five strategies were compared: no screening and screening at 1-, 2-, 3-, or 4-week intervals. Progression to severe cytomegalovirus infection was modeled on cytomegalovirus replication kinetics. Incremental cost-effectiveness ratios were calculated as a ratio of cost difference between two strategies to difference in quality-adjusted life-years starting with the low-cost strategy. One-way and probabilistic sensitivity analyses were performed to test model's robustness. RESULTS: There was an incremental gain in quality-adjusted life-years with increasing screening frequency. Incremental cost-effectiveness ratios were $783 per quality-adjusted life-year (every 4 weeks over no screening), $1861 per quality-adjusted life-year (every 3 weeks over every 4 weeks), $10,947 per quality-adjusted life-year (every 2 weeks over every 3 weeks), and $197,086 per quality-adjusted life-year (weekly over every 2 weeks). Findings were sensitive to screening cost, cost of hospitalization, postprophylaxis cytomegalovirus incidence, and graft loss after cytomegalovirus infection. No screening was favored when willingness to pay threshold was <$14,000 per quality-adjusted life-year, whereas screening weekly was favored when willingness to pay threshold was >$185,000 per quality-adjusted life-year. Screening every 2 weeks was the dominant strategy between willingness to pay range of $14,000-$185,000 per quality-adjusted life-year. CONCLUSIONS: In cytomegalovirus high-risk kidney transplant recipients, compared with no screening, screening for postprophylactic cytomegalovirus viremia is associated with gains in quality-adjusted life-years and seems to be cost effective. A strategy of screening every 2 weeks was the most cost-effective strategy across a wide range of willingness to pay thresholds.

来源:Clin J Am Soc Nephrol,查看原文。版权归原作者所有。

引用

  1. Puttarajappa CM, Hariharan S, Smith KJ, et al. A Markov Analysis of Screening for Late-Onset Cytomegalovirus Disease in Cytomegalovirus High-Risk Kidney Transplant Recipients. Clin J Am Soc Nephrol. 2017. PMID: 29025787. doi:10.2215/CJN.05080517

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。